These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 18602955)

  • 1. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic agonists as preventative therapy for Alzheimer's disease.
    Beach TG
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1633-6. PubMed ID: 12476965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of nicotinic acetylcholine receptors in Alzheimer's disease.
    Oddo S; LaFerla FM
    J Physiol Paris; 2006; 99(2-3):172-9. PubMed ID: 16448808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of cholinergic dysfunction and cognitive deficits induced by amyloid beta-peptide.
    Tran MH; Yamada K; Nabeshima T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Oct; 21(4):125-32. PubMed ID: 11769570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.
    Fuentealba RA; Farias G; Scheu J; Bronfman M; Marzolo MP; Inestrosa NC
    Brain Res Brain Res Rev; 2004 Dec; 47(1-3):275-89. PubMed ID: 15572177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease.
    Wu CK; Thal L; Pizzo D; Hansen L; Masliah E; Geula C
    Exp Neurol; 2005 Oct; 195(2):484-96. PubMed ID: 16085017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity.
    Liu Q; Wu J
    Acta Pharmacol Sin; 2006 Oct; 27(10):1277-86. PubMed ID: 17007734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
    Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
    Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
    Davis RE; Doyle PD; Carroll RT; Emmerling MR; Jaen J
    Arzneimittelforschung; 1995 Mar; 45(3A):425-31. PubMed ID: 7763338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amyloid cascade hypothesis of Alzheimer's disease and alpha 7 nicotinic receptor].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Apr; 22(2):49-53. PubMed ID: 12050852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurotransmitters in Alzheimer's disease].
    Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS
    Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
    Verhoeff NP
    Expert Rev Neurother; 2005 Mar; 5(2):277-84. PubMed ID: 15853497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease.
    Coulson EJ; May LM; Sykes AM; Hamlin AS
    Neuroscientist; 2009 Aug; 15(4):317-23. PubMed ID: 19458382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic function and Alzheimer's disease.
    Giacobini E
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S1-5. PubMed ID: 12973744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of synaptic dysfunction in Alzheimer's disease.
    Masliah E
    Histol Histopathol; 1995 Apr; 10(2):509-19. PubMed ID: 7599445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease.
    Lai MK; Tsang SW; Garcia-Alloza M; Minger SL; Nicoll JA; Esiri MM; Wong PT; Chen CP; Ramírez MJ; Francis PT
    Neurobiol Dis; 2006 Jun; 22(3):555-61. PubMed ID: 16473016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.